The IL-2 cytokine family in cancer immunotherapy
- PMID: 25200249
- DOI: 10.1016/j.cytogfr.2014.07.018
The IL-2 cytokine family in cancer immunotherapy
Abstract
The use of cytokines from the IL-2 family (also called the common γ chain cytokine family) such as interleukin (IL)-2, IL-7, IL-15, and IL-21 to activate the immune system of cancer patients is one of the most important areas of current cancer immunotherapy research. The infusion of IL-2 at low or high doses for multiple cycles in patients with metastatic melanoma and renal cell carcinoma was the first successful immunotherapy for cancer proving that the immune system could completely eradicate tumor cells under certain conditions. The initial clinical success observed in some IL-2-treated patients encouraged further efforts focused on developing and improving the application of other IL-2 family cytokines (IL-4, IL-7, IL-9, IL-15, and IL-21) that have unique biological effects playing important roles in the development, proliferation, and function of specific subsets of lymphocytes at different stages of differentiation with some overlapping effects with IL-2. IL-7, IL-15, and IL-21, as well as mutant forms or variants of IL-2, are now also being actively pursued in the clinic with some measured early successes. In this review, we summarize the current knowledge on the biology of the IL-2 cytokine family focusing on IL-2, IL-15 and IL-21. We discuss the similarities and differences between the signaling pathways mediated by these cytokines and their immunomodulatory effects on different subsets of immune cells. Current clinical application of IL-2, IL-15 and IL-21 either as single agents or in combination with other biological agents and the limitation and potential drawbacks of these cytokines for cancer immunotherapy are also described. Lastly, we discuss the future direction of research on these cytokines, such as the development of new cytokine mutants and variants for improving cytokine-based immunotherapy through differential binding to specific receptor subunits.
Keywords: Cancer; Cytokine; IL-15; IL-2; IL-21; Immunotherapy; Lymphocyte; NK cell; T-cell.
Copyright © 2014 Elsevier Ltd. All rights reserved.
Similar articles
-
Prospect of IL-2, IL-7, IL-15 and IL-21 for HIV immune-based therapy.Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2011 Nov;36(11):1037-45. doi: 10.3969/j.issn.1672-7347.2011.11.002. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2011. PMID: 22169717 Review.
-
[Antitumoral action of interferons and interleukins in combination with radiotherapy. Part I: immunologic basis].Strahlenther Onkol. 2004 Apr;180(4):187-93. doi: 10.1007/s00066-004-9119-x. Strahlenther Onkol. 2004. PMID: 15057428 Review. German.
-
Interleukin-21 signaling: functions in cancer and autoimmunity.Clin Cancer Res. 2007 Dec 1;13(23):6926-32. doi: 10.1158/1078-0432.CCR-07-1238. Clin Cancer Res. 2007. PMID: 18056166 Review.
-
Comparison of common gamma-chain cytokines, interleukin-2, interleukin-7, and interleukin-15 for the in vitro generation of human tumor-reactive T lymphocytes for adoptive cell transfer therapy.J Immunother. 2006 May-Jun;29(3):284-93. doi: 10.1097/01.cji.0000190168.53793.6b. J Immunother. 2006. PMID: 16699371
-
Adenovirus-mediated interleukin (IL)-24 immunotherapy for cancer.Methods Mol Biol. 2010;651:241-70. doi: 10.1007/978-1-60761-786-0_14. Methods Mol Biol. 2010. PMID: 20686970
Cited by
-
Tasquinimod modulates tumor-infiltrating myeloid cells and improves the antitumor immune response to PD-L1 blockade in bladder cancer.Oncoimmunology. 2016 Feb 18;5(6):e1145333. doi: 10.1080/2162402X.2016.1145333. eCollection 2016 Jun. Oncoimmunology. 2016. PMID: 27471612 Free PMC article.
-
Role of IL-2 in cancer immunotherapy.Oncoimmunology. 2016 Apr 25;5(6):e1163462. doi: 10.1080/2162402X.2016.1163462. eCollection 2016 Jun. Oncoimmunology. 2016. PMID: 27471638 Free PMC article. Review.
-
The Mechanism of Anti-PD-L1 Antibody Efficacy against PD-L1-Negative Tumors Identifies NK Cells Expressing PD-L1 as a Cytolytic Effector.Cancer Discov. 2019 Oct;9(10):1422-1437. doi: 10.1158/2159-8290.CD-18-1259. Epub 2019 Jul 24. Cancer Discov. 2019. PMID: 31340937 Free PMC article.
-
Four Cysteine Residues Contribute to Homodimerization of Chicken Interleukin-2.Int J Mol Sci. 2019 Nov 15;20(22):5744. doi: 10.3390/ijms20225744. Int J Mol Sci. 2019. PMID: 31731766 Free PMC article.
-
Effect of Natural Compounds on NK Cell Activation.J Immunol Res. 2018 Dec 25;2018:4868417. doi: 10.1155/2018/4868417. eCollection 2018. J Immunol Res. 2018. PMID: 30671486 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical